Announced details
Regenerative medicine for chronic-phase cerebral infarction and related conditions
Joint research partner conducting joint research on chronic-phase cerebral infarction and related conditions since August 2023
Osaka Medical Center, part of the National Hospital Organization. Other information on its location, representative, capital, year of establishment and business activities is not disclosed.
There is no change to the earnings forecast for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Human iPS cell-derived regenerative medicine products for chronic-phase cerebral infarction and related conditions |
| Counterparty | National Hospital Organization Osaka Medical Center |
| Counterparty overview | Osaka Medical Center, part of the National Hospital Organization. Other information on its location, representative, capital, year of establishment and business activities is not disclosed. |
| Relationship with the Company | Joint research partner conducting joint research on chronic-phase cerebral infarction and related conditions since August 2023 |
| Launch date | Initiatives toward the start of a company-sponsored clinical trial are scheduled to proceed during the joint research period. The specific start date is not disclosed. |
| Applicable area | Regenerative medicine for chronic-phase cerebral infarction and related conditions |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Based on the progress and results achieved through the joint research to date, the parties will advance specific preparations for a company-sponsored clinical trial.